Opendata, web and dolomites

MATURE-NK SIGNED

MAnufacturing of TUmour-REactive Natural Killer cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MATURE-NK project word cloud

Explore the words cloud of the MATURE-NK project. It provides you a very rough idea of what is the project "MATURE-NK" about.

training    protocol    car    student    fortify    bridge    summer    exchange    diseases    basic    trials    chimeric    checkpoint    reagents    private    building    winter    comprise    immunotechnology    treatment    industry    rights    tumor    cancer    blocking    donor    biotech    interactions    therapy    combine    competences    inhibitors    compliant    incurable    evaluation    business    biology    modulation    ligands    manufacturing    mouse    atmps    translational    property    antibody    bioinformatics    activated    modification    bispecifc    oriented    receptors    receptor    intellectual    sectors    classified    first    designed    refractory    pioneering    train    genetically    medicinal    network    nk    antigen    inhibitory    killer    therapeutic    humanized    gap    recipient    manipulated    natural    trial    groups    cell    link    unknown    portfolios    medicine    cross    models    activating    translate    anti    clinical    reactivity    modules    ligand    cells    schools    gmp    combination    therapies    personalized    experts    companies   

Project "MATURE-NK" data sheet

The following table provides information about the project.

Coordinator
MEDIZINISCHE HOCHSCHULE HANNOVER 

Organization address
address: Carl-Neuberg-Strasse 1
city: HANNOVER
postcode: 30625
website: www.mh-hannover.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙351˙662 €
 EC max contribution 3˙351˙662 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2022-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) coordinator 249˙216.00
2    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 286˙275.00
3    UNIVERSITAT BASEL CH (BASEL) participant 265˙226.00
4    INNATE PHARMA FR (MARSEILLE) participant 262˙875.00
5    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 262˙875.00
6    THE HEBREW UNIVERSITY OF JERUSALEM IL (JERUSALEM) participant 260˙300.00
7    IRCCS OSPEDALE POLICLINICO SAN MARTINO IT (GENOVA) participant 258˙061.00
8    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 255˙934.00
9    GLYCOSTEM-THERAPEUTICS B.V. NL (OSS) participant 255˙374.00
10    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 249˙216.00
11    MILTENYI BIOTEC GMBH DE (BERGISH GLADBACH) participant 249˙216.00
12    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) participant 249˙216.00
13    UNIVERSIDAD POMPEU FABRA ES (BARCELONA) participant 247˙872.00

Map

 Project objective

'This project will provide future-oriented translational research training designed to bridge the gap between basic research and applied development of new cell-based therapeutic products by the biotech industry and their clinical use for incurable diseases. This will be done on the example of activated/genetically manipulated natural killer (NK) cells, which are classified as Advanced Therapy Medicinal Products ('ATMPs'), and their use in treatment of cancer refractory to classical therapies. For this we combine experts in NK cell biology supported by bioinformatics, clinical groups pioneering NK cell therapies and biotech companies with NK cell-based portfolios. A student exchange will ensure training in basic, clinical and private sectors. Network-wide training modules organized in summer/winter schools include immunotechnology, business management and intellectual property rights. This will train competences important to translate research findings to personalized medicine. In research we build on information from clinical trials of NK cell-based therapies. We will improve anti-tumor reactivity of NK cells including selection of NK subsets and modulation of NK receptor/ligand interactions. First, this will comprise i) improved donor/recipient combination and NK subsets and ii) modification of NK cells by chimeric antigen receptors ('CAR') and bispecifc antibody reagents to cross-link NK cells to tumor targets. Second, it will fortify NK cell reactivity by i) blocking ligand interactions of inhibitory receptors ('checkpoint inhibitors') and ii) defining unknown ligands of activating NK receptors on tumor cells. Third, procedures and NK products in their best combination will be developed by i) evaluation in humanized mouse models, ii) building a GMP-compliant manufacturing process and iii) design of a clinical trial protocol. The project should provide for manufacturing of NK cell-based therapeutic products and their evaluation in clinical trials. '

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MATURE-NK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MATURE-NK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

Train2Wind (2020)

Training school on entrainment in offshore wind power

Read More  

euSNN (2019)

European School of Network Neuroscience

Read More  

5GhOSTS (2019)

5th GeneratiOn Security for Telecom Services

Read More